Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that commonly result in iron deficiency anemia (IDA) due to impaired iron absorption and chronic blood loss. Patients with IBD experience reduced health-related quality of life, with fatigue playing a key role. The aim of the present analysis was to calculate health state utility values (HSUVs) from a recent randomized controlled trial (RCT) of intravenous iron in the treatment of patients with IBD and IDA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
